Anumana’s Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag
Related Articles
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022
Mayo Clinic launches two new companies
DotMed: Mayo Clinic has launched two new companies to support its new technology initiative, the Remote Diagnostics and Management Platform. The solution applies artificial intelligence to derive insights from data…April 18, 2021
Mayo Clinic Launches Two Companies To Improve AI Diagnostic And Preventative Care
Healthcare Technology Report: Artificial Intelligence (AI) continues to improve the healthcare industry. Capitalizing on AI’s many applications, Mayo Clinic is currently launching two new ventures, Anumana and Lucem Health, in…April 28, 2021
New Philips platform offers AI-powered ECG tools from outside vendors
Royal Philips has launched the Philips ECG AI Marketplace, which gives cardiac care teams access to multiple vendor offerings in one central location. The company hopes this can help clinicians…July 25, 2025